Iceland· IS-EU/1/23/1730/001
Briumvi
A ublituximab product containing ublituximab, registered in Iceland by Neuraxpharm Pharmaceuticals S.L.. The same ATC class is registered in 12 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Ublituximab is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AG14 (ublituximab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Ublituximab · ATC L04AG14
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Ublituximab
- Manufacturer
- Neuraxpharm Pharmaceuticals S.L.
- Country
- Iceland (IS)
- ATC code
- L04AG14
- ATC class
- Ublituximab
- Defined daily dose
- 2.68 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean0522656 ml x1 hglISK 592452
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ublituximab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBRIUMVINeuraxpharm Pharmaceuticals, S.L., Barcelona
- BelgiumBriumvi 150 mgNeuraxpharm Pharmaceuticals
- FinlandBriumviNeuraxpharm Pharmaceuticals S.L.
- IrelandBriumvi 150 mg Concentrate for solution for infusionNeuraxpharm Pharmaceuticals S.L.
- NorwayBriumviNeuraxpharm Pharmaceuticals, S.L.
- SwedenBriumvi 150 mg Koncentrat till infusionsvätska, lösningNeuraxpharm Pharmaceuticals S.L.
- SwitzerlandBriumvi
- United KingdomBriumvi 150mg/6ml concentrate for solution for infusion vialsNeuraxpharm UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Briumvi
- Norway · Briumvi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/238f693b-1758-4aa4-99d7-82f14cd57896 GET /v1/drugs/238f693b-1758-4aa4-99d7-82f14cd57896?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Innrennslisþykkni, lausn",
"source": "lyfjastofnun",
"atc_raw": "L04AG14",
"marketed": true,
"strength": "150 mg",
"ma_number": "EU/1/23/1730/001",
"substance": "Ublituximab",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "45077"
}See everything about ublituximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.